Monday, June 3, 2019, Chicago, Illinois, 6:45 AM – 7:45 AM

Breakfast with the Investigators: Management of Melanoma

Location:
Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Hotel Phone: (312) 922-4400

Time:
6:15 AM - 6:45 AM — Registration and Breakfast Buffet
6:45 AM - 7:45 AM — Educational Meeting

Meeting Room:
Grand Ballroom (Level 2)

There is no registration fee for this event. However, preregistration is advised as seating is limited.  
 
Faculty:
Professor Georgina Long, BSc, PhD, MBBS
Co-Medical Director of Melanoma Institute Australia
Chair of Melanoma Medical Oncology and Translational Research
Melanoma Institute Australia and Royal North Shore Hospital
The University of Sydney
Sydney, Australia

Jason J Luke, MD
Associate Professor and Director of the Cancer Immunotherapeutic Center
University of Pittsburgh Medical Center and Hillman Cancer Center
Pittsburgh, Pennsylvania


Jeffrey S Weber, MD, PhD
Deputy Director
Laura and Isaac Perlmutter Cancer Center
Professor of Medicine
NYU Langone Medical Center
New York, New York

Moderator:
Neil Love, MD
Research To Practice
Miami, Florida

Not an official event of the 2019 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO, CancerLinQ, or Conquer Cancer.

This activity is supported by educational grants from Array BioPharma Inc, Bristol-Myers Squibb Company, Genentech, Merck and Novartis.
6:15 AM - 6:45 AM — Registration and Breakfast Buffet
6:45 AM - 7:45 AM — Educational Meeting

Meeting Agenda and Format

This unique activity will feature 3 distinct content modules during which the faculty will review available data sets, present cases from their practices and provide perspectives on key clinical questions as part of a moderated discussion. The event will not include traditional didactic lectures, and the following topics will be reviewed.

MODULE 1: Evolving Treatment Approaches for Localized or Locally Advanced Melanoma

  • Published efficacy and safety data from the Phase III CheckMate 238 trial evaluating adjuvant nivolumab versus ipilimumab for patients with resected melanoma at high risk for recurrence
  • Key efficacy outcomes from the Phase III KEYNOTE-054 trial comparing pembrolizumab to placebo after complete resection of high-risk Stage III melanoma; recent FDA approval of this approach
  • Design of, entry criteria for and primary efficacy and safety outcomes from the Phase III COMBI-AD study evaluating dabrafenib/trametinib as adjuvant treatment for high-risk melanoma with a BRAF V600 tumor mutation after surgical resection; FDA-approved dose, schedule and indication for adjuvant dabrafenib/trametinib
  • Clinical, biologic and practical factors influencing the decision to administer nivolumab, pembrolizumab or dabrafenib/trametinib as adjuvant therapy
  • Ongoing clinical trials incorporating other novel agents and immunotherapeutic approaches in the adjuvant setting

MODULE 2: Integration of BRAF/MEK Inhibitors into the Management of Metastatic Melanoma with a BRAF Tumor Mutation

  • Molecular and pharmacologic similarities and differences among various BRAF/MEK inhibitor combinations (dabrafenib/trametinib, vemurafenib/cobimetinib, encorafenib/binimetinib)
  • Key efficacy and safety outcomes from the Phase III COLUMBUS trial evaluating the combination of encorafenib/binimetinib versus vemurafenib or encorafenib monotherapy for patients with unresectable or metastatic melanoma with a BRAF tumor mutation
  • FDA approval of encorafenib/binimetinib and clinical, biologic and practical factors affecting the selection of a specific BRAF/MEK inhibitor combination
  • Incidence, prevention and management of side effects and toxicities associated with available BRAF/MEK inhibitor combinations
  • Available data sets examining the use of targeted therapy after disease progression on an immune checkpoint inhibitor or vice versa; optimal sequencing for patients who are candidates for both of these approaches

MODULE 3: Current and Future Role of Immune Checkpoint Inhibitors in the Management of Metastatic Melanoma

  • Long-term follow-up from the Phase III CheckMate 067 trial of nivolumab/ipilimumab versus nivolumab or ipilimumab alone for previously untreated unresectable advanced melanoma; clinical, biologic and practical factors influencing the use of anti-PD-1 monotherapy versus combination therapy
  • Optimal management of BRAF wild-type disease that has progressed on or after adjuvant immune checkpoint inhibitor therapy
  • Efficacy and safety of immune checkpoint inhibition in patients with brain metastases
  • Role, if any, of PD-L1 expression as a predictive marker of response to immune checkpoint inhibitors; other potential predictors of response to immune checkpoint inhibition (eg, tumor mutational burden)
  • Early research data combining anti-PD-1/PD-L1 antibodies with BRAF and/or MEK inhibitors for metastatic melanoma
  • Biologic rationale for, published research findings with and ongoing investigation of promising novel therapies (eg, relatlimab, bempegaldesleukin)

Target Audience:
This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of melanoma.

Learning Objectives:
At the conclusion of this activity, participants should be able to:

  • Identify patients after surgical removal of primary melanoma for whom adjuvant therapy should be considered, and counsel these individuals regarding the risks and potential benefits of existing and recently approved systemic approaches.
  • Consider age, performance status and other disease-related factors to guide the selection of first- and later-line therapy for patients with metastatic BRAF wild-type melanoma.
  • Use available clinical trial evidence to safely and effectively incorporate targeted and immunotherapeutic approaches into the management of metastatic melanoma with a BRAF tumor mutation.
  • Recognize the recent FDA approval of the combination of the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib for patients with unresectable or metastatic melanoma with a BRAF tumor mutation, and consider how the availability of this strategy affects current therapeutic algorithms.
  • Identify adverse events associated with immune checkpoint inhibitors, targeted therapies and other systemic treatments for melanoma, and offer supportive management strategies to minimize or manage side effects.
  • Recall the design of ongoing clinical trials evaluating anti-PD-1/PD-L1 antibodies in combination with other systemic therapies (eg, targeted therapy) for patients with advanced melanoma, and counsel appropriate patients about availability and participation.
  • Recall new data with other investigational agents and strategies demonstrating promising activity in melanoma, and discuss ongoing trial opportunities with eligible patients.

CME Credit Form:
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Supporters:
This activity is supported by educational grants from Array BioPharma Inc, Bristol-Myers Squibb Company, Genentech, Merck and Novartis.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Hotel Phone: (312) 922-4400

Meeting Room:
Grand Ballroom (Level 2)

Directions:
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.

 

Thank you for your interest in our educational program. At this time, online preregistration is closed. However, seats are still available for the conference. Onsite registration will be open starting at 6:15 AM on Monday, June 3rd. If you are interested in attending, please visit our registration desk in the Grand Ballroom foyer located on the second level of the Hilton Chicago (720 Michigan Avenue, Chicago, IL).

Please note, onsite registrant seating will be prioritized for healthcare professionals directly involved in the treatment of patients, and meal service will be offered based on availability. If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com or call (800) 233-6153.